Is retroelement-based gene editing a safer alternative to CRISPR-Cas approaches?

In a Perspective, Stephen Tang and Samuel Sternberg discuss retroelement-based gene editing as a safer alternative to CRISPR-Cas approaches.

Pharmalittle: We’re reading about Medicare negotiations, U.K. drug rebates rising, and more

Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and reassuring. After all, that oh-so-familiar routine of phone

March 17, 2025

Philips consent decree ‘worse case scenario’ for respiratory business

Philips’ U.S. sleep and respiratory care business could be set back by years as it now faces a consent decree from the Food and Drug

February 6, 2024

Fresh Blood Not Always the Best Blood?

Longer storage of red blood cell (RBC) units was associated with longer transplant survival in kidney transplant patients receiving early transfusions, a retrospective study in

September 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.